Charles River Laboratories International (NYSE:CRL) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Charles River Laboratories International PS Ratio Related Terms
Charles River Laboratories International PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International PS Ratio Chart
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International PS Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's PS Ratio distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's PS Ratio falls into.
Charles River Laboratories International PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Charles River Laboratories International's Share Price of today is $226.79. Charles River Laboratories International's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $81.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Charles River Laboratories International (CRL) has a PS Ratio of 2.77 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Charles River Laboratories International and its competitors. This is near median its historical median of 2.73. Over the past decade, Charles River Laboratories International's PS Ratio has ranged from 1.28 to 7.16. According to the industry distribution chart, Charles River Laboratories International ranks #96 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 48%.
Is Charles River Laboratories International's PS Ratio too high?
Charles River Laboratories International's current PS Ratio of 2.77 is near median its 10-year median of 2.73. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 7.16. The Medical Diagnostics & Research industry median PS Ratio is 2.83. Charles River Laboratories International's value of 2.77 is 2.1% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #96 out of 200 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's PS Ratio compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #96 out of 200 companies for PS Ratio. This puts Charles River Laboratories International in the upper half of its industry. The industry median PS Ratio is 2.83. Charles River Laboratories International's value of 2.77 is 2.1% below this benchmark. Historically, Charles River Laboratories International's own PS Ratio has ranged from 1.28 to 7.16 over the past decade. While the company's 10-year median is 2.73 vs. the industry median of 2.83, Charles River Laboratories International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Diagnostics & Research company?
The median PS Ratio among Medical Diagnostics & Research companies is 2.83, based on 200 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current PS Ratio of 2.77 is 2.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median PS Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current PS Ratio is 2.77, which is near median its own 10-year median of 2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.68, compared to a current price of $226.79 — trading 16.5% above its estimated fair value. The current PS Ratio is 2.77, which is near median its 10-year median of 2.73 and 2.1% below the Medical Diagnostics & Research industry median of 2.83. Charles River Laboratories International's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current PS Ratio is 2.77 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $226.79 is trading 16.5% above its estimated GF Value™ of $194.68.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for CRL:
PS Ratio: 2.77 (near median its 10-year median of 2.73)
GF Value™: $194.68 vs. price of $226.79 (16.5% above fair value)
Industry Position: 2.1% below the Medical Diagnostics & Research median (#96 of 200)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for CRL
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
